journal
MENU ▼
Read by QxMD icon Read
search

Current Cancer Drug Targets

journal
https://www.readbyqxmd.com/read/29032751/development-in-drug-targeting-and-delivery-in-cervical-cancer
#1
Urvashi Aggarwal, Amit Kumar Goyal, Goutam Rath
Cervical cancer is the second most common cancer in women. Standard treatment options available for cervical cancer including chemotherapy, surgery and radiation therapy associated with their own side effects and toxicities. Tumor-targeted delivery of anticancer drugs is perhaps one of the most appropriate strategies to achieve optimal outcomes from treatment and improve quality of life. Recently nanocarriers based drug delivery systems owing to their unique properties have been extensively investigated for anticancer drug delivery...
October 9, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28969556/ponatinib-a-review-of-efficacy-and-safety
#2
Fulvio Massaro, Matteo Molica, Massimo Breccia
Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I mutation. In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations. For this reason, ponatinib is currently indicated for the treatment of chronic myeloid leukaemia (CML) in every phase of disease resistant and/or intolerant to dasatinib and nilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation. The drug is also indicated for Ph+ acute lymphoblastic leukaemia (ALL)...
October 2, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28969555/oxidative-stress-and-cancer-the-role-of-nrf2
#3
Soraya Sajadimajd, Mozafar Khazaei
Oxidative stress due to imbalance between ROS production and detoxification plays the pivotal role in determining cell fate. In response to excessive ROS, apoptotic signaling pathway is activated to promote normal cell death. However, through deregulation of biomolecules, high amount of ROS promotes carcinogenesis in cells with defective signaling factors. In this line, NRF2 appears to be as the master regulator to protect cells from oxidative and electrophilic stress. Nrf2 is an intracellular transcription factor that regulates the expression of a number of genes to encode anti-oxidative enzymes, detoxifying factors, anti-apoptotic proteins and drug transporters...
October 2, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28969535/the-pi3k-pathway-at-the-crossroads-of-cancer-and-the-immune-system-strategies-for-next-generation-immunotherapy-combinations
#4
Dearbhaile Collins, Maxime Chenard-Poirier, Juanita Lopez
Immunotherapy has led to a paradigm shift in the treatment of some malignancies, providing long-term, durable responses for a subset of patients with advanced cancers. Increasingly, research has identified links between the immune system and critical oncogenic growth factor pathways. The phosphoinositide 3-kinase (PI3K)-AKT-mTOR cascade is frequently hyperactivated in cancer, and plays an integral role in many cellular processes including tumour growth and survival and can underlie resistance to therapies. In this review, we first summarize two key learnings from the initial studies of inhibitors of this pathway, including the profile of immune-related adverse events such as colitis, transaminitis and pneumonitis and the increased incidence of infections with the majority of agents that target the PI3K-AKT-mTOR pathway...
September 26, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28914191/neoisoliquiritigenin-inhibits-tumor-progression-by-targeting-grp78-%C3%AE-catenin-signaling-in-breast-cancer
#5
Hailin Tang, Fu Peng, Xiaojia Huang, Xinhua Xie, Bo Chen, Jiangang Shen, Fei Gao, Jieshu You, Xiaoming Xie, Jianping Chen
Although breast cancer mortality has been stable or decreasing in the world, its incidence and recurrence rates have sharply risen worldwide in recent years. Identification of novel preventative biomarkers and drugs for breast cancer has become an urgent issue worldwide. Recently, GRP78 demonstrated a critical role in mediating tumorigenesis, metastasis and angiogenesis. However, the impact of GRP78 in breast cancer and clinical characteristics remains unclear. In this study, we found that GRP78 could promote breast cancer initiation and progression, and higher expression of GRP78 indicated poorer state of breast cancer patients, suggesting that GRP78 was a significant oncogene with the potential to be a novel biomarker and target in clinical investigation...
September 14, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28875836/coinhibitory-molecule-pd-1-as-a-therapeutic-target-in-the-microenvironment-of-multiple-myeloma
#6
Djordje Atanackovic, Tim Luetkens, Mary Steinbach, Nicolaus Kröger
Immunological dysfunction in the microenvironment of multiple myeloma is a potential target for immune-mediated therapies. The programmed death 1 (PD-1) receptor is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on tumor cells and inhibits T-cell-mediated apoptosis. Inhibiting such "checkpoint" by monoclonal antibodies recently has been shown high activity in solid tumors and malignant lymphomas. In patients with multiple myeloma PD-L1 is overexpressed on myeloma cells and PD1 on T-cells suggesting an active role of PD- 1/PD-L1 in the immunosuppressive microenvironment...
September 6, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28820056/involvement-of-cd24-in-multiple-cancer-related-pathways-makes-it-an-interesting-new-target-for-cancer-therapy
#7
Shirin Eyvazi, Bahram Kazemi, Siavoush Dastmalchi, Mojgan Bandehpour
CD24 (cluster of differentiation 24) is a small heavy glycosylated protein, which is overexpressed in many cancer and some cancer stem cells and is associated with the development, invasion, and metastasis of cancer cells. The exact role of CD24 in these processes is not fully understood, however, in this article, it has been tried to present collection of cancer-related mechanisms attributed to CD24. Based on the literature, CD24 dis-regulates different signaling pathways in various cancer cells, including; Src kinases, STAT3, EGFR, Wnt/β-catenin and MAPK...
August 18, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28786349/aldose-reductase-inhibitor-fidarestat-prevents-high-fat-diet-induced-intestinal-polyps-in-apcmin-mice
#8
Ashish Saxena, Ravinder Tammali, Kota V Ramana, Satish K Srivastava
BACKGROUND: Recent epidemiological and experimental studies have shown that obesity is a major risk factor for colorectal cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. Previously, we have shown that inhibition of polyol pathway enzyme aldose reductase (AR) prevents carcinogens- and inflammatory growth factors-induced CRC. However, the effect of AR inhibition on a high-fat diet (HFD)-induced formation of intestinal polyps in Apc-deficient Min (multiple intestinal neoplasia; ApcMin/+) mice is not known...
August 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28786348/clinical-evidence-on-the-magnitude-of-change-in-growth-pathway-activity-in-relation-to-tamoxifen-resistance-is-required
#9
Sepideh Mansouri, Leila Farahmand, Azin Teymourzadeh, Keivan Majidzadeh-A
BACKGROUND: Despite prolonged disease-free survival and overall survival rates in estrogen receptor (ER)-positive patients undergoing adjuvant treatment, Tamoxifen therapy tends to fail due to eventual acquisition of resistance. OBJECTIVE: Although numerous studies have emphasized the role of receptor tyrosine kinases (RTKs) in the development of Tamoxifen resistance, inadequate clinical evidence is available regarding the alteration of biomarker expression during acquired resistance, thus undermining the validity of the findings...
August 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28782471/tgf-%C3%AE-1-causes-emt-by-regulating-n-acetyl-glucosaminyl-transferases-via-downregulation-of-non-muscle-myosin-ii-a-through-jnk-p38-pi3k-pathway-in-lung-cancer
#10
Ghulam Jilany Khan, Yingsheng Gao, Ming Gu, Lai Wang, Sara Khan, Farah Naeem, Bashir Alsiddig Yousef, Debmalya Roy, Herve Semukunzi, Shengtao Yuan, Li Sun
BACKGROUND: Epithelial to mesenchymal transition (EMT) is a major determinant of cancer metastasis and is closely linked with TGF-β1. Intracellular proteins, including E. Cadherin, N. Cadherin and Vimentin are directly related to EMT that affect cell migration and adhesion; on the other hand, non muscle myosin (NM) has a central role in cytokinesis, migration and adhesion. OBJECTIVE: We aimed to explore the association of EMT and metastasis with TGF-β1 through regulation of non-muscle myosin II-A (NMII-A) and its interaction with Hexosamine Biosynthesis Pathway (HBP)...
August 7, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28699500/cell-derived-exosomes-as-promising-carriers-for-drug-delivery-and-targeted-therapy
#11
Xinyi Wang, Haiyang Zhang, Haiou Yang, Ming Bai, Tao Ning, Shuang Li, Jialu Li, Ting Deng, Guoguang Ying, Yi Ba
Exosomes are small vesicles that are secreted by various types of cells, known to mediate signal transduction between cells. During recent years, novel carriers for the delivery of targeted drugs, chemotherapy drugs and RNAs are under development, which is believed to be beneficial for patients. Considering issues of drug nano-formulations in bloodstream, such as nano-toxicity and rapid clearance by mononuclear phagocyte system, exosomes derived from either patient's cells or bodyfluids, seem to be an optimal option...
July 10, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669340/oncolytic-tanapoxvirus-expressing-interleukin-2-is-capable-of-inducing-the-regression-of-human-melanoma-tumors-in-the-absence-of-t-cells
#12
Tiantian Zhang, Dennis H Kordish, Yogesh R Suryawanshi, Rob R Eversole, Steven Kohler, Charles D Mackenzie, Karim Essani
Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-2 (IL-2), a T-cell growth factor, plays a critical role in activating T cells, natural killer (NK) cells and macrophages in both the innate and adaptive immune system. In this study, a recombinant TANV expressing mouse IL-2 (TANVΔ66R/mIL-2) was generated, where the viral thymidine kinase (TK) gene (66R) was replaced with the mIL-2 transgene...
June 30, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669339/dna-fragmentation-cell-cycle-arrest-and-docking-study-of-novel-bis-spiro-cyclic-2-oxindole-of-pyrimido-4-5-b-quinoline-4-6-dione-derivatives-against-breast-carcinoma
#13
Magda F Mohamed, Amr Mohamed Abdelmoniem, Ahmed H M Elwahy, Ismail A Abdelhamid
An efficient one pot synthesis of bis spiro-cyclic 2-oxindole derivatives of pyrimido[4,5-b]quinoline-4,6-dione using 6-aminouracil, bis-isatin and dimedone has been developed. The cytotoxic effect against different human cell lines MCF7, HCT116 and A549 cell lines was evaluated. The derivative 6a, was found the most encouraging compound in this series and it was selected for molecular studies against MCF7. Our data indicated that compound 6a is an attractive target for breast cancer, as it inhibits proliferation, cell cycle progression and induces apoptosis of tumor cells...
June 30, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669338/microrna-key-to-angiogenesis-regulation-mirna-biology-and-therapy
#14
Ankit Tiwari, Bratati Mukherjee, Manjusha Dixit
Angiogenesis is involved in maintaining normal physiological processes like embryonic development, wound healing, inflammation and reproduction. Pathogenesis of various diseases like diabetic retinopathy, rheumatoid arthritis and cancer are associated with imbalanced angiogenesis. Angiogenic stimulators and inhibitors act together for keeping angiogenic switch in balance. Recently miRNAs have been found to regulate various stages of angiogenesis. miRNAs are 21-23 nucleotides long, single stranded, noncoding RNA molecules generated endogenously...
June 30, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669337/synthetic-lethality-from-research-to-precision-cancer-nanomedicine
#15
Anuradha Gupta, Anas Ahmad, Aqib Iqbal Dar, Rehan Khan
Cancer is an evolutionary disease with multiple genetic alterations, accumulated due to chromosomal instability and/or aneuploidy and it sometimes acquires drug-resistant phenotype also. Whole genome sequencing and mutational analysis helped in understanding the differences among persons for predisposition of a disease and its treatment non-responsiveness. Thus, molecular targeted therapies came into existence. Among them, the concept of synthetic lethality have enthralled great attention as it is a pragmatic approach towards exploiting cancer cell specific mutations to specifically kill cancer cells without affecting normal cells and thus enhancing anti-cancer drug therapeutic index...
June 30, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669336/the-safety-efficacy-and-therapeutic-potential-of-histone-deacetylase-inhibitors-with-special-reference-to-panobinostat-in-gastrointestinal-tumors-a-review-of-preclinical-and-clinical-studies
#16
Avineesh Singh, Preeti Patel, Jageshwar, Vijay Kumar Patel, Deepak Kumar Jain, M Kamal, Harish Rajak
Histone deacetylase inhibitors (HDACi) have demonstrated as an emerging class of anticancer drugs involved in regulation of gene expression and chromatin remodeling thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobinostat (Farydac®, LBH589) is developed by Novartis Pharmaceuticals and a newly US FDA approved drug for the multiple myeloma. It is under clinical investigation for a range of hematological and solid tumors worldwide in both oral and intravenous formulations...
June 30, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669349/recent-updates-on-the-therapeutic-potential-of-her2-tyrosine-kinase-inhibitors-for-the-treatment-of-breast-cancer
#17
Heena Singla, Anjana Munshi, Raja Paramjit Singh Banipal, Vinod Kumar
HER2 positive breast cancer is characterized by the low survival rate in the metastatic patients. Development of resistance and disease-relapse are the major problems associated with the currently available therapies for HER2 positive breast cancer. There are two major targeted therapies for HER2 positive breast cancer viz. monoclonal antibodies and tyrosine-kinase inhibitors, and both of these therapies have their advantages and limitations. To address the limitations associated with the existing therapies, use of antibodies and TKIs as combination therapy proved to be more effective...
June 23, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669348/the-structural-bioinformatics-analysis-of-biophenolic-lignan-estrogen-receptor-interaction
#18
Farzaneh Mohamadyar-Toupkanlou, Mina Esfandiari, Mahshid Sadat Kashef-Saberi, Mahboubeh Kabiri Renani, Masoud Soleimani
BACKGROUND: Plant lignans have proven efficacious in blocking estrogen receptors of breast cancer cells. However, available studies have mostly dealt with anti-cancer effects of groups of lignans in certain foods or plants and the effects of specific lignans, especially from a molecular interaction viewpoint, has been rarely addressed in the literature. OBJECTIVE: We aimed to computationally predict the binding ability and binding strength of pinoresinol, matairesinol, lariciresinol and secoisolariciresinol as potent ligands of estrogen receptor alpha (ER-α), in order to study these lignans as drugs...
June 23, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669347/evaluation-of-anti-cancer-activity-of-stilbene-and-methoxydibenzo-b-f-oxepin-derivatives
#19
Damian Garbicz, Damian Mielecki, Michał Wrzesiński, Tomasz Pilżys, Michał Marcinkowski, Jan Piwowarski, Janusz Dębski, Ewelina Palak, Przemysław Szczeciński, Hanna Krawczyk, Elżbieta Grzesiuk
BACKGROUND: Stilbenes, 1,2-diphenylethen derivatives, including resveratrol and combretastatins, show anticancer features especially against tumor angiogenesis. Fosbretabulin, CA-4, in combination with carboplatin, is in the last stages of clinical tests as an inhibitor of thyroid cancer. The mode of action of these compounds involves suppression of angiogenesis through interfering with tubulin (de)polymerization. OBJECTIVE: We have previously synthesized five E-2-hydroxystilbenes and seven dibenzo[b,f]oxepins in Z configuration, with methyl or nitro groups at varied positions...
June 23, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28669346/crizotinib-versus-chemotherapy-on-alk-positive-nsclc-%C3%AF-a-systematic-review-of-efficacy-and-safety
#20
Mingxia Wang, Guanqi Wang, Haiyan Ma, Baoen Shan
Introduction Crizotinib was approved to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by the Food and Drug Administration in 2011.We conducted a systematic review of clinical trials and retrospective studies to compare the efficacy and safety of crizotinib with chemotherapy. Methods We searched electronic databases from inception to Dec. 2016. Clinical trials and retrospective studies regarding crizotinib and crizotinib versus chemotherapy in treatment of NSCLC were eligible...
June 23, 2017: Current Cancer Drug Targets
journal
journal
39549
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"